



EWOC-1

Elderly Women Ovarian Cancer

Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage IIB-IV advanced ovarian cancer


First ENGOT-GCIG international study of elderly patients in Ovarian Cancer

Participating Groups

GINECO, AGO, MITO, ANZGOG, Canada, JGOG, GOTIC, NSGO




EWOC-1 Flow chart



PRIMARY ENDPOINT

To compare the rate of success to deliver 6 courses of chemotherapy without progression at 6 months or unacceptable toxicity* of 3 different regimens in vulnerable elderly patients



* Unacceptable Toxicity = is defined as a major adverse event related to chemotherapy or treatment procedures leading either to early treatment stopping, to an unplanned hospital admission or to death.

SECONDARY ENDPOINTS

➤ Overall Survival (OS)

➤ Quality of life (QOL) :

☐ FACT-O

Following last GCIG SB meeting, addition of 2 general questions

- How would you rate your overall health during the past week?

- How would you rate your overall quality of life during the past week?


➤ Safety and tolerability

➤ Geriatric Covariates and patient outcome

➤ Aging biomarkers and patient outcome

What about EWOC-1 Registry ?

To collect information
on all elderly OC
patients



From a French survey performed on 20 sites, vulnerable patients will account for 50% of diagnosed patients

Registry should include **500 patients** (Ewoc-1 and non vulnerable patients)



EWOC-1 Status

May 2013

French HA and EC approval

Nov 2013

First inclusions in France



❖ **International coordination to be started now**

GCIIG Participation : AGO, MITO, NSGO, Canada , JGOG, DGOG

❖ **Interested** : KGOG and Shangai GOG